

### **AMENDMENTS TO THE CLAIMS**

The following listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A composition suitable for administration to a subject, said composition comprising an antigen bearing target and a fusion polypeptide, said fusion polypeptide comprising

a first amino acid sequence which can bind to a carbohydrate

and

a second amino acid sequence comprising a ligand for a cell surface polypeptide of a leukocyte,

wherein said composition includes said fusion polypeptide bound to a carbohydrate on said antigen bearing target and includes said fusion polypeptide which is not bound to said antigen bearing target.

2. (Previously presented) The composition of claim 1, wherein said ligand is chosen from the group: a ligand for a cytokine receptor, a ligand for CD40, a ligand for an adhesion molecule, a ligand for a defensin receptor, a ligand for a heat shock protein receptor, a ligand for a T cell costimulatory molecule, a ligand for a counterreceptor for a T cell costimulatory molecule, a ligand for an opsonin receptor.

3. (Currently amended) The ~~vaccine~~ composition of claim 2 wherein said ligand comprises at least five contiguous amino acids of a naturally occurring cytokine, said cytokine being chosen from the group: GM-CSF, an interleukin, a chemokine, an interferon, a TNF-alpha, a flt-3 ligand.

4. (Withdrawn) The vaccine composition of claim 2 wherein said ligand comprises at least about five contiguous amino acids of a naturally occurring CD154 molecule.

5. (Previously presented) The composition of claim 1, wherein said antigen bearing target is chosen from the group: a tumor cell, a virus, a bacterial cell, a fungal cell, a cell of a parasite, a prion, a mammalian cell, an insect cell, and a polypeptide free of other cell-derived material.
6. (Previously presented) The composition of claim 5, wherein said antigen bearing target is pathogenic.
7. (Previously presented) The composition of claim 5, wherein said antigen bearing target is attenuated.
8. (Currently amended) The composition of claim 1, wherein said antigen bearing target is a cell which ~~is substantially unable to divide~~ divides at a rate that is less than about 50% of the rate of division of corresponding cells which are not treated to prevent cell division.
9. (Previously presented) The composition of claim 1, wherein said leukocyte is an antigen presenting cell.
10. (Previously presented) The composition of claim 9, wherein said leukocyte is a professional antigen presenting cell.
11. (Previously presented) The composition of claim 9, wherein said leukocyte is a dendritic cell.
12. (Previously presented) The composition of claim 1, wherein said first amino acid sequence can bind to a sialic acid on a glycoprotein.
13. (Previously presented) The composition of claim 1, wherein said first amino acid sequence comprises a carbohydrate-binding domain of a naturally occurring lectin.

10/666,833

Application No. ~~10/666,886~~  
Amendment dated June 11, 2011  
Office Action of March 11, 2011

Docket No.: 85849DIV4(308597)

14. (New) The composition of claim 8, wherein said cell divides at a rate that is less than about 30-50% of the rate of division of corresponding cells which are not treated to prevent cell division.